There are two main biomarkers which use fluid in the lungs to diagnose pleural mesothelioma. One is a protein called fibulin-3 and the other is called soluable mesothelin related peptide or SMRP. A new study published in the International Journal of Cancer Research tracked use of the biomarkers in 120 patients. The 120 patients included 33 with malignant pleural mesothelioma, 64 with benign tumors, and 23 patients with various other types of cancer that had metastasized in the pleura.
Researchers concluded that fibulin-3 was unable to differentiate between the pleural effusion of mesothelioma and other types of cancers. Fibulin-3 however can still be useful as a prognosis marker. Unlike fibulin-3, SMRP was able to distinguish between the various types of cancers and thus a much more accurate diagnostic tool for mesothelioma patients. The AntiCancer Research findings were consistent with previous studies.
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers.
